Pomalidomide Submitted to FDA; Carfilzomib to Be Discussed June 20 at the Oncologic Drugs Advisory Committee
For patients eagerly awaiting news of new treatments, Celgene announced today that pomalidomide has been submitted to the FDA. If it is approved, pomalidomide could be available late this year. The FDA also announced the Oncologic Drugs Advisory Committee will discuss ONYX Pharmaceuticals' carfilzomib on June 20th. The committee recommendation usually guides the FDA decision on approval, but it is not binding.The IMF will have more to say about these developments and we will be closely watching the FDA actions. OVERVIEW OF LATEST TREATMENTS
10th Annual Robert A. Kyle Lifetime Achievement Award
The IMF has chosen Professor Jesus San-Miguel as recipient of the 2012 Robert A. Kyle Lifetime Achievement Award. The award, named for its first recipient, honors an outstanding physician whose body of work in the field of myeloma has made significant advances in research, treatment and care of myeloma patients. Prof. San-Miguel will receive the award during the International Myeloma Working Group’s 3rd Annual Summit this summer in Amsterdam. READ MORE
IMF Nurse Leadership Board Member Honored
Beth Faiman, member of the IMF Nurse Leadership Board, has received the 2012 Excellence in Medical Oncology Award from the Oncology Nursing Society. A certified nurse practitioner at the Cleveland Clinic, Faiman is also a full-time pre-doctoral research fellow at Case Western Reserve. You can listen to an IMF teleconference Faiman recently led on “Living Well With Myeloma,” READ MORE
Celebrating Cancer Drug Legislation Victories Across the US!
From Delaware to Hawaii, cancer patient advocates are taking action to open their state legislators’ eyes to outdated health care policies that cause financial burdens and – even worse – prevent patients from getting life-saving treatments. READ MORE
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
jc test
10 PASSI PER CURA MIGLIORE®
10 Steps to Better Care® 10 Steps to Stress Control – From Fear to Hope
10 Steps to Happy Holidays
2011 IMF Holiday Gift Boutique
New Study: The Search for Criteria to Diagnose Active Myeloma at an Early Stage
Comprender El Tratamiento con Dosis Altas con Rescate de Células Madre
Conference aired at 1:00 pm CEST/7:00 am Eastern/4:00 am Pacific
ABOUT BSRI™
ABOUT BSRI™
Advocacy Update - April 2013
Advocacy Update - March 2013
Advocacy Update - September 2012
Advocacy Update: The Healthcare Landscape in the Aftermath of the 2012 Elections
As the Bill Turns...Episode 3
ASCO 2012: Dr. Pashos - Race- and health-related quality of life among patients newly diagnosed with multiple myeloma
ASCO 2013: Dr. Jakubowiak - Treatment outcome with the combination of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) for newly diagnosed multiple myeloma (NDMM) after extended follow-up.
ASCO 2013: Dr. Lonial - Phase (Ph) I/II study of elotuzumab (Elo) plus lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety.
ASCO 2013: Dr. Pandey - Beneficial effect of complete response and type of therapy in multiple myeloma.
ASCO 2013: Dr. Usmani - Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM).
ASCO 2013: Dr. Weisel - MM-003: A phase III, multicenter, randomized, open-label study of pomalidomide (POM) plus low-dose dexamethasone (LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM).
ASH 2012: A PREVIEW
Audio Recording of Consensus on Care: Management of Side Effects of Novel Therapies Teleconference
Breaking News: Pomalyst® (pomalidomide) Approved by the FDA for Relapsed Myeloma
FDA Recognition of Extended Survival with VELCADE® Indicates Important New Progress in Treating the Disease
Health Reform and You: The ABC’s of the ACA for Private Health Insurance
IMF 6th Annual Comedy Celebration benefiting the Peter Boyle Research Fund October 27, 2012
IMF Board Member Edith Mitchell, M.D., FACP, Named 2012 Recipient Of ASCO Humanitarian Award
IMF Nurse Leadership Board (NLB) White Paper on Subcutaneous Velcade® (bortezomib)
IMF Responds to Proposed Changes in CMS PET Scan Policy
It is Officially Myeloma Awareness Month Across the Country!
jc test
Live from ASH 2012: Journalists’ Workshop with Leading Myeloma Experts
Live! The Boca Raton Patient & Family Seminar
Living Well with Myeloma Teleconference Series:
How to Prevent Infection in Myeloma Patients
Myelom Merkur - Frühjahr 2012 - #901
MYELOMA AWARENESS MONTH 2012 FACT-A-DAY
Myeloma Canada Announces Recipient of this Year’s Research Grant
Myeloma Minute
April 11, 2013
Myeloma Minute
April 18, 2013
Myeloma Minute
February 7, 2013
Myeloma Minute
January 31, 2013
Myeloma Minute
July 26, 2012
Myeloma Minute
June 28, 2012
Myeloma Minute
March 7, 2013
Myeloma Minute
May 17, 2012
Myeloma Minute
November 8, 2012
Myeloma Minute
October 25, 2012
Myeloma Minute June 13, 2013
Myeloma Minute May 24, 2012
Myeloma Today Spring 2013
New! Free Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
Should Myeloma Patients Get a Flu Shot? If So, Which One?
Special Myeloma Minute on FDA Approved Data for VELCADE®, including long-term survival data
STEP 7: CONSOLIDATION AND MAINTENANCE - ARE THEY NEEDED? REFERENCES
STEP 8: KEEPING TRACK OF THE MYELOMA - MONITORING WITHOUT MYSTERY
Stillwater, Minn., Myeloma Support Group Marks "Centennial" Anniversary
Teleconference: Myeloma Updates 2012
Post ASCO/EHA/IMWG Summit
The Emerging Role of Kyprolis in the Treatment Paradigm
The Hope Society
THE IMF AT ASH 2012
The IMF Spearheads New Coalition’s First Meeting on State Health Exchanges
The Importance of Clinical Trial Participation - A teleconference with Dr. Brian G. M. Durie September 8,2011
The International Myeloma Foundation to Convene First Global Leaders Summit in Stockholm to Raise Disease Awareness and Increase Access to Life-Saving Treatments
Клиническое значение электрофореза белковых фракций
step 1: get the correct diagnosis
publications
back
print
related videos
related articles
